Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atovaquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.82 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atovaquone SCHEMBL21694 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL20769805 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL637069 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL1542719 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL29559044 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL8848607 | 1.00 | MAPT (0.82) | MAPTKMT2AMEN1LMNAUSP2 | |
| Atovaquone SCHEMBL8851283 | 0.90 | MAPT (0.67) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL21695 | 0.90 | MAPT (1.00) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL1649508 | 0.90 | MAPT (1.00) | MAPTKMT2AMEN1LMNAUSP2 | |
| SCHEMBL28082527 | 0.89 | MAPT (0.73) | MAPTKMT2AMEN1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048246-B1 | MITOCHONDRIA-TARGETED ATOVAQUONE: A MORE POTENT AND MORE EFFECTIVE ANTITUMOR, ANTIMICROBIAL, AND ANTIMALARIAL DRUG | MEDICAL COLLEGE WISCONSIN INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230218547-A1 | CHEMICAL COMPOSITION | THE JOHN HOPKINS UNIVERSITY | 2023-07-13 | — | — | US | disclosed |
| US-20230201135-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | ELEVAID THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201135-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | ELEVAID THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230111793-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230017373-A1 | Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220265566-A1 | ATOVAQUONE NANOPARTICULATE COMPOSITIONS | TULEX PHARMACEUTICALS INC (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022144920-A1 | ATOVAQUONE PRODRUGS | IPCA LABORATORIES LIMITED (IN) | 2022-07-07 | — | — | WO | disclosed |
| EP-3345594-B1 | SOLUBILIZED FLAVONOID COMPOSITION | TECH INVESTMENTS LC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210179524-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2021-06-17 | — | — | US | disclosed |
| US-20100069428-A1 | ACRIDONE COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2010-03-18 | — | — | US | disclosed |
| WO-2010023686-A2 | CRYSTALLINE FORM OF 2-CHLORO-3-[4-(4-CHLOROPHENYL) CYCLOHEXYL] [1,4]NAPHTHOQUINONE, PROCESS FOR THE SAME AND USE FOR PRODUCING 2-[4-(4-CHLOROPHENYL)CYCLOHEXYL]-3- HYDROXY- 1,4- NAPHTHOQUINONE | MATRIX LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | WO | disclosed |
| US-20100028425-A1 | PHARMACEUTICAL COMPOSITION OF ATOVAQUONE | GLENMARK GENERICS LTD. (IN) | 2010-02-04 | — | — | US | disclosed |
| US-20100028425-A1 | PHARMACEUTICAL COMPOSITION OF ATOVAQUONE | GLENMARK GENERICS LTD. (IN) | 2010-02-04 | — | — | US | disclosed |
| WO-2010001379-A1 | A PROCESS FOR PREPARING ATOVAQUONE AND ASSOCIATE INTERMEDIATES | CHEMAGIS LTD. (IL) | 2010-01-07 | — | — | WO | disclosed |
| US-20090105350-A1 | Process for the preparation of atovaquone | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105350-A1 | Process for the preparation of atovaquone | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
| WO-2009007996-A2 | CYCLODEXTRIN COMPLEXES OF ATOVAQUONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007991-A2 | A NEW PROCESS FOR PREPARATION OF ATOVAQUONE AND NOVEL INTERMEDIATES THEREOF | IPCA LABORATORIES LIMITED (IN) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008122988-A1 | PROCESS FOR PREPARATION OF ATOVAQUONE AND THE CONVERSION OF CIS-ISOMER TO TRANS- ISOMER | CADILA HEALTHCARE LIMITED (IN) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265566-A1 | ATOVAQUONE NANOPARTICULATE COMPOSITIONS | RECQL, ATIC, POLQ | MAPT 1168/4885KMT2A 1080/4885MEN1 1959/4885 |
| US-20230218547-A1 | CHEMICAL COMPOSITION | NDUFA10, NDUFA3, NDUFB10 | MAPT 897/4885KMT2A 1883/4885MEN1 1962/4885 |
| US-20210179524-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | GPX4, MPO, G6PD | MAPT 1240/4885KMT2A 2654/4885MEN1 1766/4885 |
| US-20100028425-A1 | PHARMACEUTICAL COMPOSITION OF ATOVAQUONE | CYP2C19, NDUFA10, ATP6V1H | MAPT 1090/4885KMT2A 3310/4885MEN1 1939/4885 |
| US-20230017373-A1 | Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial Drug | MAVS, MT-ATP6, MT-ND2 | MAPT 2733/4885KMT2A 1927/4885MEN1 1436/4885 |
| US-20090105350-A1 | Process for the preparation of atovaquone | POLQ, ATIC, CYP2S1 | MAPT 2334/4885KMT2A 1620/4885MEN1 3858/4885 |
| US-20230111793-A1 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | GPX4, MPO, G6PD | MAPT 1240/4885KMT2A 2654/4885MEN1 1766/4885 |
| US-20100069428-A1 | ACRIDONE COMPOUNDS | ACR, ABCC1, SLC11A2 | MAPT 294/4885KMT2A 3587/4885MEN1 3731/4885 |
| US-20230201135-A1 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | IL4I1, MPO, TPMT | MAPT 2698/4885KMT2A 2285/4885MEN1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.